Choose Your Country or Region

VE-821

Name: VE-821
Brand: Selleck Chemicals
SKU: S8007
Rating: 5 (258 reviews)

Synonyms: ATR inhibitor IV

Catalog No.S8007 Purity:99.74%

VE-821(ATR inhibitor IV) is a potent and selective ATP competitive inhibitor of ATR with K_i/IC50 of 13 nM/26 nM in cell-free assays, shows inhibition of H2AX phosphorylation, minimal activity against PIKKs ATM, DNA-PK, mTOR and PI3Kγ.

VE-821 Chemical Structure

CAS No. 1232410-49-9

Purity & Quality Control

Batch: Purity: 99.74%

99.74

VE-821 Related Products

Related Targets	ATM ATR	Click to Expand
Related Products	KU-55933 KU-60019 Berzosertib (VE-822) Ceralasertib (AZD6738) AZ20 AZD0156 Mirin AZD1390 CP-466722 Elimusertib (BAY-1895344) hydrochloride ETP-46464 Elimusertib (BAY-1895344) CGK 733 VX-803 (M4344) AZ31 AZ32 HAMNO	Click to Expand
Related Compound Libraries	FDA-approved Drug Library Natural Product Library Apoptosis Compound Library DNA Damage/DNA Repair compound Library Cell Cycle compound library	Click to Expand

Signaling Pathway

ATM/ATR Signaling Pathway

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
U2OS	Growth Inhibition Assay			IC50～0.8 μM	25593184
SAOS2	Growth Inhibition Assay			IC50～0.8 μM	25593184
CAL72	Growth Inhibition Assay			IC50～0.8 μM	25593184
NOS1	Growth Inhibition Assay			IC50～0.8 μM	25593184
HUO9	Growth Inhibition Assay			IC50～0.8 μM	25593184
MG63	Growth Inhibition Assay			IC50～9 μM	25593184
SJSA1	Growth Inhibition Assay			IC50～9 μM	25593184
MDA-MB-231	Cytotoxicity Assay	1/3/10 μM	1 h	potentiates the cytotoxicity of both camptothecin and LMP-400	25269479
HT-29	Cytotoxicity Assay	1/3/10 μM	1 h	potentiates the cytotoxicity of both camptothecin and LMP-400	25269479
HCT-116 p53+/+	Cytotoxicity Assay	1/3/10 μM	1 h	potentiates the cytotoxicity of both camptothecin and LMP-400	25269479
HCT-116 p53-/-	Cytotoxicity Assay	1/3/10 μM	1 h	potentiates the cytotoxicity of both camptothecin and LMP-400	25269479
TF-1	Growth Inhibition Assay	0.011–8 μM	96 h	enhances the antiproliferative effects of MK1775	24179152
HEL	Growth Inhibition Assay	0.011–8 μM	96 h	enhances the antiproliferative effects of MK1775	24179152
THP-1	Growth Inhibition Assay	0.011–8 μM	96 h	enhances the antiproliferative effects of MK1775	24179152
HL-60	Function Assay	10 mM	0.5 h	reduces phosphorylation of Chk1 at serine 345	23934411
OVCAR-8	Function Assay	1 µM	24 h	abrogates chemotherapy-induced cell cycle arrest	23548269
PANC-1	Growth Inhibition Assay	0.11-9 μM	1 h	inhibits the cell viability in a dose- dependent manner	22825331
MiaPaCa	Growth Inhibition Assay	0.11-9 μM	1 h	inhibits the cell viability in a dose- dependent manner	22825331
PSN-1	Growth Inhibition Assay	0.11-9 μM	1 h	inhibits the cell viability in a dose- dependent manner	22825331
K562	Apoptosis assay	10 uM	48 hrs	Induction of apoptosis in human K562 cells assessed as gammaH2AX/53BP1 levels at 10 uM after 48 hrs by DAPI staining based immunofluorescence microscopy in presence of 25 to 250 pM (-)-lomaiviticin A	27177826
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
MDCK	Cytotoxicity assay	500 nM	1 hr	Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability at 500 nM pretreated for 1 hr followed by 2 Gy irradiation under normoxic condition by Alamar blue assay	27823879
MDCK	Cytotoxicity assay	500 nM	1 hr	Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability at 500 nM pretreated for 1 hr followed by 4 Gy irradiation under anoxic condition by Alamar blue assay	27823879
MDCK	Cytotoxicity assay	500 nM	72 hrs	Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability at 500 nM pretreated for 72 hrs followed by 72 hrs incubation under normoxic condition by Alamar blue assay	27823879
MDCK	Cytotoxicity assay	500 nM	72 hrs	Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability at 500 nM after 72 hrs under anoxic condition by Alamar blue assay	27823879
Click to View More Cell Line Experimental Data

Biological Activity

Description

Targets

ATR ^[1]
(Cell-free assay)

13 nM(Ki)

In vitro
In vitro	VE-821(ATR inhibitor IV) shows excellent selectivity for ATR with minimal cross-reactivity against the related PIKKs ATM, DNA-PK, mTOR and PI3K (K_is of 16 μM, 2.2 μM, >1 μM and 3.9 μM, respectively. VE-821 alone commits a large fraction of cancer cell populations to death, but it only reversibly limits cell cycle progression in normal cells, with minimal death or long-term detrimental effects. ^[1] VE-821(ATR inhibitor IV) inhibits H2AX cell growth with IC50 of 800 nM. ^[2]
Kinase Assay	Kinase inhibition
Kinase Assay	The ability of compounds to inhibit ATR, ATM or DNAPK kinase activity istested using a radiometric-phosphate incorporation assay. A stock solution isprepared consisting of the appropriate buffer, kinase, and target peptide. To this isadded the compound of interest, at varying concentrations in DMSO to a final DMSO concentration of 7%. Assays are initiated by addition of an appropriate [γ-³³P]ATP solution and incubated at 25 ℃. Assays are stopped, after the desired time course, by addition of phosphoric acid and ATP to a final concentration of 100 mM and 0.66μM, respectively. Peptides are captured on a phosphocellulose membrane, prepared as per manufacturer
Cell Research	Cell lines	H2AX cells
	Concentrations	--
	Incubation Time	96 hours
	Method	Cells are plated in 96-well plates and allowed to adhere overnight. The following day, compounds are added at the indicated concentrations in a final volume of 200μL, and the cells are then incubated for 96 h. MTS reagent (40μL) isthen added, and 1 h later, absorbance at 490 nm ismeasured using a SpectraMax Plus 384 plate reader. Synergy and antagonism are assessed using Macsynergy software.
Experimental Result Images	Methods	Biomarkers	Images	PMID
	Western blot	E-cadherin / Vimentin / ZEB1 Vimentin p-AKT / AKT / p-ERK / ERK		29157079
	Growth inhibition assay	Cell viability		29157079

In Vivo
In vivo	VE-821(ATR inhibitor IV) is a potent and selective ATP competitive inhibitor of ATR.
Animal Research	Animal Models	Male immunodefcient mice
	Dosages	15 mg/kg
	Administration	i.p.

References

Chemical Information & Solubility

Molecular Weight	368.41	Formula	C₁₈H₁₆N₄O₃S
CAS No.	1232410-49-9	SDF	Download VE-821 SDF
Smiles	CS(=O)(=O)C1=CC=C(C=C1)C2=CN=C(C(=N2)C(=O)NC3=CC=CC=C3)N
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 74 mg/mL ( (200.86 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molecular Weight Calculator

In vivo Batch: Add solvents to the product individually and in order.				In vivo Formulation Calculator
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	30%PEG400 1 0.5%Tween80 2 5%propylene glycol Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	30.000mg/ml (81.43mM)	Taking the 1 mL working solution as an example, add 300 μL of 100 mg/ml clarified PEG400 stock solution to 5 μL of Tween80, mix evenly to clarify it; add 50 μL Propylene glycol to the above system, mix evenly to clarify it; then continue to add 645 μL ddH2O to adjust the volume. to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):